Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

5
results for

"Joo Ho Lee"

Article category

Keywords

Publication year

"Joo Ho Lee"

Original Articles

Hepatic neoplasm

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
Young Eun Chon, Dong Yun Kim, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Yeonjung Ha, Joo Ho Lee, Kwan Sik Lee, Beodeul Kang, Jung Sun Kim, Hong Jae Chon, Do Young Kim
Clin Mol Hepatol 2024;30(3):345-359.
Published online March 12, 2024
DOI: https://doi.org/10.3350/cmh.2023.0553
Background/Aims
Atezolizumab plus bevacizumab (ATE+BEV) therapy has become the recommended first-line therapy for patients with unresectable hepatocellular carcinoma (HCC) because of favorable treatment responses. However, there is a lack of data on sequential regimens after ATE+BEV treatment failure. We aimed to investigate the clinical outcomes of patients with advanced HCC who received subsequent systemic therapy for disease progression after ATE+BEV.
Methods
This multicenter, retrospective study included patients who started second-line systemic treatment with sorafenib or lenvatinib after HCC progressed on ATE+BEV between August 2019 and December 2022. Treatment response was assessed using the Response Evaluation Criteria in Solid Tumors (version 1.1.). Clinical features of the two groups were balanced through propensity score (PS) matching.
Results
This study enrolled 126 patients, 40 (31.7%) in the lenvatinib group, and 86 (68.3%) in the sorafenib group. The median age was 63 years, and males were predominant (88.1%). In PS-matched cohorts (36 patients in each group), the objective response rate was similar between the lenvatinib- and sorafenib-treated groups (5.6% vs. 8.3%; P=0.643), but the disease control rate was superior in the lenvatinib group (66.7% vs. 22.2%; P<0.001). Despite the superior progression- free survival (PFS) in the lenvatinib group (3.5 vs. 1.8 months, P=0.001), the overall survival (OS, 10.3 vs. 7.5 months, P=0.353) did not differ between the two PS-matched treatment groups.
Conclusions
In second-line therapy for unresectable HCC after ATE+BEV failure, lenvatinib showed better PFS and comparable OS to sorafenib in a real-world setting. Future studies with larger sample sizes and longer follow-ups are needed to optimize second-line treatment.

Citations

Citations to this article as recorded by  Crossref logo
  • Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab–bevacizumab
    Heechul Nam, Dong Yun Kim, Do Young Kim, Ji Hoon Kim, Chang Wook Kim, Jaejun Lee, Keungmo Yang, Ji Won Han, Pil Soo Sung, Seung Kew Yoon, Hee Sun Cho, Hyun Yang, Si Hyun Bae, Soon Kyu Lee, Jung Hyun Kwon, Soon Woo Nam, Ahlim Lee, Do Seon Song, U Im Chang,
    Hepatology.2026; 83(5): 1098.     CrossRef
  • Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab
    Hyung-Don Kim, Sun Jin Sym, Hong Jae Chon, Moonho Kim, Jung Hun Kang, Baek-Yeol Ryoo, Choong-kun Lee, Joohyun Hong, Hyewon Ryu, Woo Kyun Bae, Hyeyeong Kim, Hyunho Kim, Jin Won Kim, Tae-Yong Kim, Changhoon Yoo
    Journal of Hepatology.2026; 84(2): 308.     CrossRef
  • Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma
    Kazuki Maesaka, Hayato Hikita, Yuki Tahata, Chinatsu Nishioka, Machiko Kai, Kumiko Shirai, Kazuhiro Murai, Yuki Makino, Yoshinobu Saito, Takahiro Kodama, Kazuyoshi Ohkawa, Masanori Miyazaki, Yasutoshi Nozaki, Takayuki Yakushijin, Ryotaro Sakamori, Nobuyuk
    Journal of Gastroenterology.2026; 61(1): 68.     CrossRef
  • Post-immunotherapy second-line strategies for hepatocellular carcinoma: State of the art and ongoing trials
    Sara Ascari, Rusi Chen, Andrea De Sinno, Bernardo Stefanini, Matteo Cescon, Matteo Serenari, Cristina Mosconi, Francesco Tovoli
    World Journal of Gastroenterology.2026;[Epub]     CrossRef
  • Identifying sorafenib benefit among patients with hepatocellular carcinoma: A transcriptomic and genomic approach
    Sun Young Yim, Hayeon Kim, Tae Hyung Kim, Sang-Hee Kang, Youngwoo Lee, Eunho Choi, Yang Jae Yoo, Seong Hee Kang, Young-Sun Lee, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kyung Suk Yang, Yitao Tang, Bowha Sohn, Yun Seong Jeong, Hyewon P
    JHEP Reports.2026; 8(4): 101742.     CrossRef
  • Lenvatinib as Second-Line Regimen after Atezolizumab plus Bevacizumab Combination Therapy
    Masatoshi Kudo
    Liver Cancer.2026; 15(1): 1.     CrossRef
  • Efficacy and Safety of Intensity‐Modulated Radiotherapy Combined With Regorafenib With or Without Immune Checkpoint Inhibitors as Second‐Line Treatment for Advanced Hepatocellular Carcinoma: A Real‐World Cohort Study From a Single Center
    Lingxia Xin, Zhiyu Li, Yirui Zhai, Liming Wang, Feng Ye, Yongkun Sun, Wen Zhang, Tiago Biachi de Castria, Sanjaya K. Satapathy, Vishal G. Shelat, Shaffer R. S. Mok, Jennifer Wu, Shulian Wang, Yueping Liu, Yongwen Song, Yuan Tang, Hao Jing, Hui Fang, Shuna
    Cancer Medicine.2026;[Epub]     CrossRef
  • Advances in the Management of Hepatocellular Carcinoma: Evolving Systemic Therapy, Perioperative Strategies, and Care for Special Populations
    Jing He, Xiao-Qin Wu, Zhen-Guang Wang
    Journal of Clinical Question.2026; 3(2): e114.     CrossRef
  • Current and Emerging Immunotherapy Strategies in Hepatocellular Carcinoma: Standard Treatments and Biomarkers
    Yoonseok Lee
    Journal of Digestive Cancer Research.2026; 14(1): 53.     CrossRef
  • Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
    Chinatsu Nishioka, Yuki Tahata, Kazuki Maesaka, Machiko Kai, Kumiko Shirai, Kazuhiro Murai, Yuki Makino, Yoshinobu Saito, Yasutoshi Nozaki, Tasuku Nakabori, Hisashi Ishida, Takayuki Yakushijin, Sadaharu Iio, Nobuyuki Tatsumi, Kazuho Imanaka, Naruyasu Kaki
    PLOS One.2026; 21(5): e0341395.     CrossRef
  • EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
    Bruno Sangro, Josepmaria Argemi, Maxime Ronot, Valerie Paradis, Tim Meyer, Vincenzo Mazzaferro, Peter Jepsen, Rita Golfieri, Peter Galle, Laura Dawson, Maria Reig
    Journal of Hepatology.2025; 82(2): 315.     CrossRef
  • Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
    Jaekyung Cheon, Shigeo Shimose, Hyung-Don Kim, Takashi Niizeki, Min-Hee Ryu, Tomotake Shirono, Baek-Yeol Ryoo, Hideki Iwamoto, Changhoon Yoo
    Journal of Cancer Research and Clinical Oncology.2025;[Epub]     CrossRef
  • Treatment for hepatocellular carcinoma after immunotherapy
    Landon L. Chan, Tsz Tung Kwong, Johnny C.W. Yau, Stephen L. Chan
    Annals of Hepatology.2025; 30(2): 101781.     CrossRef
  • Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study
    Christian Möhring, Moritz Berger, Farsaneh Sadeghlar, Xin Zhou, Taotao Zhou, Malte Benedikt Monin, Kateryna Shmanko, Sabrina Welland, Friedrich Sinner, Birgit Schwacha-Eipper, Ulrike Bauer, Christoph Roderburg, Angelo Pirozzi, Najib Ben Khaled, Peter Schr
    Cancers.2025; 17(6): 972.     CrossRef
  • Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real‐World Analysis of the IMMUreal Cohort
    Najib Ben Khaled, Valentina Zarka, Bernard Hobeika, Julia Schneider, Monika Rau, Alexander Weich, Hans Benno Leicht, Liangtao Ye, Ignazio Piseddu, Michael T. Dill, Arne Kandulski, Matthias Pinter, Ursula Ehmer, Peter Schirmacher, Jens U. Marquardt, Julia
    Alimentary Pharmacology & Therapeutics.2025; 61(11): 1755.     CrossRef
  • Application of the associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) technique in conversion therapy for hepatocellular carcinoma
    Jingyun Ning, Cao Dai, Qin Liu, Haoming Lin, Rui Zhang
    British Journal of Surgery.2025;[Epub]     CrossRef
  • Recent advances in polydopamine-coated metal–organic frameworks for cancer therapy
    Jingchao He, Guangtian Wang, Yongfang Zhou, Bin Li, Pan Shang
    Frontiers in Bioengineering and Biotechnology.2025;[Epub]     CrossRef
  • Targeting STAT3 by erianin to overcome sorafenib resistance in hepatocellular carcinoma: Integrated network pharmacology with molecular docking, dynamics simulations, and in vitro validation
    Zixian Liu, Ruoning Qian, Yuanchao Feng, Ruogu Qi, Zhengguang Zhang, Fuqiong Zhou
    Biochemical and Biophysical Research Communications.2025; 778: 152348.     CrossRef
  • PEGylated liposomal metformin overcomes pharmacokinetic barriers to trigger potent mitochondrial disruption and cell cycle arrest in hepatocellular carcinoma
    Zeinab A. Elzanaty, Medhat W. Shafaa, Seifeldin Elabed, Mohamed M. Omran
    Scientific Reports.2025;[Epub]     CrossRef
  • Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab
    Jaekyung Cheon, Baek-Yeol Ryoo, Hong Jae Chon, Hyung-Don Kim, Min-Hee Ryu, Kyu-Pyo Kim, Beodeul Kang, Richard S. Finn, Stephen Lam Chan, Changhoon Yoo
    Liver Cancer.2025; 14(4): 446.     CrossRef
  • Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
    Pasquale Lombardi, Jung Sun Kim, Giulia F. Manfredi, Ciro Celsa, Claudia A.M. Fulgenzi, Antonio D’Alessio, Bernardo Stefanini, Niraj C. Doshi, Emily Warmington, Thomas U. Marron, Matthias Pinter, Bernhard Scheiner, Beodeul Kang, Ho Yeong Lim, Wei-Fan Hsu,
    JHEP Reports.2025; 7(12): 101595.     CrossRef
  • Mesenchymal Stem Cell-Mediated Targeted Drug Delivery Systems for Hepatocellular Carcinoma: Current Advances and Future Directions
    Yang Gao, Jian-Ping Wang, De-Fei Hong, Chang Yang, Hua Naranmandura
    Bioengineering.2025; 12(11): 1206.     CrossRef
  • The potential of lenvatinib in breast cancer therapy
    Yuefeng Shang, Tong Liu, Wenjing Wang
    Medical Oncology.2024;[Epub]     CrossRef
  • Sorafenib and SIAIS361034, a novel PROTAC degrader of BCL-xL, display synergistic antitumor effects on hepatocellular carcinoma with minimal hepatotoxicity
    Xiaoyi Zhang, Yachuan Tao, Zhongli Xu, Biao Jiang, Xiaobao Yang, Taomin Huang, Wenfu Tan
    Biochemical Pharmacology.2024; 230: 116542.     CrossRef
  • Second-line systemic therapy after atezolizumab plus bevacizumab: Is it time to boldly go beyond the known?
    Edoardo G. Giannini
    Digestive and Liver Disease.2024; 56(12): 2077.     CrossRef
  • Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
    Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim
    Clinical and Molecular Hepatology.2024; 30(4): 1005.     CrossRef
  • Improved survival with second-line hepatic arterial infusion chemotherapy after atezolizumab-bevacizumab failure in hepatocellular carcinoma
    Ji Yeon Lee, Jaejun Lee, Suho Kim, Jae-sung Yoo, Ji Hoon Kim, Keungmo Yang, Ji Won Han, Jeong Won Jang, Jong Yong Choi, Seung Kew Yoon, Ho Jong Chun, Jung Suk Oh, Pil Soo Sung
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • 21,145 View
  • 542 Download
  • 28 Web of Science
  • Crossref

Viral hepatitis

Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B
Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kwang-il Kim, Soo-Hwan Kim, Kyu Sung Rim, Seong Gyu Hwang
Clin Mol Hepatol 2019;25(1):52-64.
Published online October 23, 2018
DOI: https://doi.org/10.3350/cmh.2018.0040
Background/Aims
Nonalcoholic fatty liver disease (NAFLD) is becoming a worldwide epidemic, and is frequently found in patients with chronic hepatitis B (CHB). We investigated the impact of histologically proven hepatic steatosis on the risk for hepatocellular carcinoma (HCC) in CHB patients without excessive alcohol intake.
Methods
Consecutive CHB patients who underwent liver biopsy from January 2007 to December 2015 were included. The association between hepatic steatosis (≥ 5%) and subsequent HCC risk was analyzed. Inverse probability weighting (IPW) using the propensity score was applied to adjust for differences in patient characteristics, including metabolic factors.
Results
Fatty liver was histologically proven in 70 patients (21.8%) among a total of 321 patients. During the median (interquartile range) follow-up of 5.3 (2.9–8.3) years, 17 of 321 patients (5.3%) developed HCC: 8 of 70 patients (11.4%) with fatty liver and 9 of 251 patients (3.6%) without fatty liver. The five-year cumulative incidences of HCC among patients without and with fatty liver were 1.9% and 8.2%, respectively (P=0.004). Coexisting fatty liver was associated with a higher risk for HCC (adjusted hazards ratio [HR], 3.005; 95% confidence interval [CI], 1.122–8.051; P=0.03). After balancing with IPW, HCC incidences were not significantly different between the groups (P=0.19), and the association between fatty liver and HCC was not significant (adjusted HR, 1.709; 95% CI, 0.404–7.228; P=0.47).
Conclusions
Superimposed NAFLD was associated with a higher HCC risk in CHB patients. However, the association between steatosis per se and HCC risk was not evident after adjustment for metabolic factors.

Citations

Citations to this article as recorded by  Crossref logo
  • Antiviral Therapy Reduces Hepatocellular Carcinoma and Cirrhosis Risk in Chinese Chronic Hepatitis B Patients With Mildly Elevated Alanine Aminotransferase
    Jian Wang, Zhiyi Zhang, Li Zhu, Tao Fan, Ye Xiong, Shaoqiu Zhang, Chao Jiang, Shengxia Yin, Xin Tong, Juan Xia, Xiaomin Yan, Renling Yao, Yu Shi, Xingxiang Liu, Chuanwu Zhu, Chao Wu, Rui Huang
    Clinical Gastroenterology and Hepatology.2026;[Epub]     CrossRef
  • Steatosis Paradox: Unraveling Pathways of Suppressive Effect of Hepatic Steatosis on Hepatitis B Virus
    Shang-Chin Huang, Jia-Horng Kao
    Biomedical Journal.2026; : 100969.     CrossRef
  • Treatment strategies for patients with hepatitis B virus infection coexisting with hepatitis C virus or metabolic dysfunction-associated steatotic liver disease
    Chieh Liu, Yi-Fen Shih, Chun-Jen Liu
    Clinical and Molecular Hepatology.2026; 32(2): 565.     CrossRef
  • High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs
    Emi Sometani, Hayato Hikita, Kazuhiro Murai, Hidenori Toyoda, Satoshi Tanaka, Tsugiko Oze, Jihyun Sung, Akiyoshi Shimoda, Makoto Fukuoka, Satoshi Shigeno, Keisuke Fukutomi, Kumiko Shirai, Yuki Tahata, Yoshinobu Saito, Akira Nishio, Kunimaro Furuta, Takahi
    Hepatology Research.2025; 55(1): 22.     CrossRef
  • Risk Stratification of Metabolic Risk Factors and Statin Use Associated With Liver and Nonliver Outcomes in Chronic Hepatitis B
    Xinrong Zhang, Vy H Nguyen, Leslie Yeeman Kam, Scott D Barnett, Linda Henry, Ramsey Cheung, Mindie H Nguyen
    The Journal of Infectious Diseases.2025; 231(4): 1079.     CrossRef
  • Coexisting steatotic liver disease is not associated with long-term liver-related events in patients with chronic hepatitis B
    Navavee Uman, Apichat Kaewdech, Pimsiri Sripongpun, Naichaya Chamroonkul, Teerha Piratvisuth
    Gastroenterology Report.2025;[Epub]     CrossRef
  • Association of concomitant MASLD and hepatitis B virus with clinical prognosis in hepatocellular carcinoma after curative resection
    Chih-Jan Ko
    American Journal of Cancer Research.2025; 15(2): 737.     CrossRef
  • Study on Ultrasound-Assisted Diagnosis of CHB Complicated with NAFLD Hepatic Fibrosis Based on Deep Learning
    Xiuling Huang, Shan Huang, Changfeng Dong, Nuo Chen, Yuxuan Wang, Changmiao Wang, Yongquan Zhang, Cheng Feng
    Journal of Imaging Informatics in Medicine.2025; 38(6): 4349.     CrossRef
  • The outcomes and mechanisms of chronic hepatitis B complicated by metabolic dysfunction-associated steatotic liver disease
    Mao-Ping Li, Kai-Zhong Luo
    Hepatobiliary & Pancreatic Diseases International.2025; 24(5): 476.     CrossRef
  • Impact of Metabolic Dysfunction-Associated Fatty Liver Disease of Varying Severity on Antiviral Treatment Outcomes and Clinical Prognosis in Patients with Chronic Hepatitis B: A Systematic Review and Meta-analysis
    Qianqian Zhu, Chengde Su, Mingdan Li, Yali Xu, Qian Liu, Ying Zhang, Xinyi Zhang, Qiuxiang Li, Huajun Wang, Yawen Luo, Ping Yang
    Infectious Diseases and Therapy.2025; 14(8): 1599.     CrossRef
  • Chronic hepatitis B: Is it time for expanded antiviral treatment?
    Manish Manrai, Atul A Jha, Aditya V Pachisia, Saurabh Dawra
    World Journal of Virology.2025;[Epub]     CrossRef
  • Hepatocellular carcinoma risk stratification to identify patients suitable for intensive surveillance in viral hepatitis: the SELECT score
    Yeun-Yoon Kim, Won Chang, Jeong Min Lee, Se Woo Kim, Jae Seok Bae, Jeongin Yoo, Sun Kyung Jeon, HeeSoo Kim, Young Hoon Kim, Jin-Young Choi, Eun Ju Cho, Yun Bin Lee, Sook-Hyang Jeong, Do Young Kim, Yunhee Choi, Jeong Hee Yoon
    European Radiology.2025; 36(4): 2929.     CrossRef
  • Influence of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with HBV-related acute-on-chronic liver failure
    Rui-Min Lai, Li-Xi Yao, Shan Lin, Jia-Hui Zhou, Bing-Ping Liu, Zhao-Yi Liang, Tianbin Chen, Jia-Ji Jiang, Qi Zheng, Yueyong Zhu
    Expert Review of Gastroenterology & Hepatology.2024; 18(1-3): 103.     CrossRef
  • Review on article of effects of tenofovir alafenamide and entecavir in chronic hepatitis B virus patients
    Yu-Tong Sun, Qian-Qian Chen
    World Journal of Hepatology.2024; 16(1): 109.     CrossRef
  • Effect of metabolic dysfunction‑associated fatty liver disease on the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A systematic review and meta‑analysis
    Sixing Shen, Lingyan Pan
    Experimental and Therapeutic Medicine.2024;[Epub]     CrossRef
  • Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B
    Danny Con, Steven Tu, Daniel Clayton-Chubb, John S. Lubel, Amanda J. Nicoll, Rohit Sawhney, Stephen Bloom
    Digestive Diseases and Sciences.2024; 69(4): 1496.     CrossRef
  • Influence of nonalcoholic fatty liver disease on response to antiviral treatment in patients with chronic hepatitis B: A meta-analysis
    Shi-Yi Liu, Dian Wang, Jing Liu, Lu-Ping Yang, Gong-Ying Chen
    World Journal of Hepatology.2024; 16(3): 465.     CrossRef
  • Navigating the Nomenclature of Liver Steatosis: Transitioning from NAFLD to MAFLD and MASLD - Understanding Affinities and Differences
    Apichat Kaewdech, Pimsiri Sripongpun
    Siriraj Medical Journal.2024; 76(4): 234.     CrossRef
  • Nonalcoholic fatty liver disease in Sub-Saharan Africa: A descriptive study of the range of histopathological findings in the South-West zone of Nigeria
    Olusegun Sylvester Ojo, Olusegun Adekanle, Dennis Ndububa, Olawunmi Kolawole, Omolade Adefolabi Betiku
    Nigerian Journal of Gastroenterology and Hepatology.2024; 16(1): 42.     CrossRef
  • Hepatic macrophage niche: a bridge between HBV-mediated metabolic changes with intrahepatic inflammation
    Jun Wang, Hongzhou Lu, Qian Li
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Prevalence of nonalcoholic fatty liver disease in patients with hepatitis B: A meta-analysis
    Li Zhang, Hong-Di Wu, Yuan-Fang Qian, Hong-Yan Xu
    World Journal of Clinical Cases.2024; 12(25): 5749.     CrossRef
  • Chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease: Metabolic risk factors are key drivers of hepatocellular carcinoma
    Gupse Adali, Huseyin Aykut, Nermin Mutlu Bilgic, Yusuf Yilmaz
    Heliyon.2024; 10(18): e37990.     CrossRef
  • Revolutionizing the understanding of liver disease: Metabolism, function and future
    Arnulfo E Morales-Galicia, Mariana M Ramírez-Mejía, Guadalupe Ponciano-Rodriguez, Nahum Méndez-Sánchez
    World Journal of Hepatology.2024; 16(12): 1365.     CrossRef
  • Hepatic steatosis: Ultrasound assessment using attenuation imaging (ATI) with liver biopsy correlation
    Christopher J Welman, Jacqualine Saunders, Marilyn Zelesco, Steven Abbott, Glenn Boardman, Oyekoya T Ayonrinde
    Journal of Medical Imaging and Radiation Oncology.2023; 67(1): 45.     CrossRef
  • Concomitant Diseases and Co-contribution on Progression of Liver Stiffness in Patients with Hepatitis B Virus Infection
    Chang-Hai Liu, Wei Jiang, Dong-Bo Wu, Qing-Min Zeng, You-Juan Wang, Hong Tang
    Digestive Diseases and Sciences.2023; 68(4): 1605.     CrossRef
  • The interplay of long noncoding RNAs and hepatitis B virus
    Nima Sarfaraz, Srinivas Somarowthu, Michael J. Bouchard
    Journal of Medical Virology.2023;[Epub]     CrossRef
  • Steatosis, HBV‐related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta‐analysis
    Xianhua Mao, Ka Shing Cheung, Chengzhi Peng, Lung‐Yi Mak, Ho Ming Cheng, James Fung, Noam Peleg, Howard H.‐W. Leung, Rajneesh Kumar, Jeong‐Hoon Lee, Amir Shlomai, Man‐Fung Yuen, Wai‐Kay Seto
    Hepatology.2023; 77(5): 1735.     CrossRef
  • Letter: metabolic dysfunction‐associated fatty liver disease increases risk of all‐cause mortality in patients with chronic hepatitis C
    Qianwen Zhao, Yunlei Deng
    Alimentary Pharmacology & Therapeutics.2023; 57(2): 272.     CrossRef
  • The association of fatty liver and risk of hepatocellular carcinoma in HBV or HCV infected individuals: a systematic review and meta-analysis
    Cheng-Long Han, Bao-Wen Tian, Chun-Cheng Yang, Ya-Fei Yang, Yun-Long Ma, Zi-Niu Ding, Lun-Jie Yan, Hui Liu, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Dong-Xu Wang, Tao Li
    Expert Review of Gastroenterology & Hepatology.2023; 17(2): 189.     CrossRef
  • Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis
    Lili Liu, Hong Li, Yang Zhang, Jing Zhang, Zhenhuan Cao
    Heliyon.2023; 9(1): e13113.     CrossRef
  • Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection
    Haifeng Lv, Yanming Jiang, Geli Zhu, Shiyi Liu, Dian Wang, Jie Wang, Ke Zhao, Jing Liu
    Scientific Reports.2023;[Epub]     CrossRef
  • Positive hepatitis B core antibody is associated with advanced fibrosis and mortality in nonalcoholic fatty liver disease
    Pengyan Zhang, Zhenqiu Liu, Hong Fan, Tingting Shi, Xinyu Han, Chen Suo, Xingdong Chen, Tiejun Zhang
    European Journal of Gastroenterology & Hepatology.2023; 35(3): 294.     CrossRef
  • A novel non‐invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD
    Jian Wang, Rui Huang, Jiacheng Liu, Ruimin Lai, Yilin Liu, Chuanwu Zhu, Yuanwang Qiu, Zebao He, Shengxia Yin, Yuxin Chen, Xiaomin Yan, Weimao Ding, Qi Zheng, Jie Li, Chao Wu
    Journal of Viral Hepatitis.2023; 30(4): 287.     CrossRef
  • Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease
    You-Wen Tan, Jia-Min Wang, Xing-Bei Zhou
    World Journal of Hepatology.2023; 15(2): 237.     CrossRef
  • Impact of MAFLD on the complications after hepatectomy in patients with HBV-related hepatocellular carcinoma
    Ke-Gong Xiong, Tai-Shun Lin, Jin-Feng Kong, Qing-Biao Lin, Li-Fang Chen, Kun-Yu Ke
    Medicine.2023; 102(9): e33062.     CrossRef
  • Pyroptosis, Metabolism, and Oxidation in Tumorigenesis: Mechanisms and Therapeutic Implications
    Qi Cao, Jia-Bao Zhang, Di-Yang Sun, Jiang-Tao Fu, Wen-Bin Wu, Xiao-Fei Chen, Dong-Jie Li, Pei Wang
    Antioxidants & Redox Signaling.2023; 39(7-9): 512.     CrossRef
  • The hepatitis B virus promotes the progression of non-alcoholic fatty liver disease through incomplete autophagy
    Yang Wang, Jiaxi Li, Shanshan Wang, Yuheng Pang, Pengxiang Liu, Bangxiang Xie, Shuangshuang Dou, Tongwang Yang, Xiaoni Liu, Ying Shi, Dexi Chen
    Free Radical Biology and Medicine.2023; 204: 326.     CrossRef
  • Impact of prior HBV, HAV, and HEV infection on non‐alcoholic fatty liver disease
    Stephanos Vassilopoulos, Markos Kalligeros, Athanasios Vassilopoulos, Fadi Shehadeh, Gregorio Benitez, Matthew Kaczynski, Ingrid Lazaridou, Kittichai Promrat, Jack R. Wands, Eleftherios Mylonakis
    Journal of Viral Hepatitis.2023; 30(8): 685.     CrossRef
  • Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
    Byeong Geun Song, Sung Chul Choi, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik
    JHEP Reports.2023; 5(9): 100810.     CrossRef
  • Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis
    Yu Jun Wong, Vy H. Nguyen, Hwai-I Yang, Jie Li, Michael Huan Le, Wan-Jung Wu, Nicole Xinrong Han, Khi Yung Fong, Elizebeth Chen, Connie Wong, Fajuan Rui, Xiaoming Xu, Qi Xue, Xin Yu Hu, Wei Qiang Leow, George Boon-Bee Goh, Ramsey Cheung, Grace Wong, Vince
    Clinical and Molecular Hepatology.2023; 29(3): 705.     CrossRef
  • The Global Prevalence of Nonalcoholic Fatty Liver Disease and its Association With Cancers: Systematic Review and Meta-Analysis
    Nor Asiah Muhamad, Nur Hasnah Maamor, Fatin Norhasny Leman, Zuraifah Asrah Mohamad, Sophia Karen Bakon, Mohd Hatta Abdul Mutalip, Izzah Athirah Rosli, Tahir Aris, Nai Ming Lai, Muhammad Radzi Abu Hassan
    Interactive Journal of Medical Research.2023; 12: e40653.     CrossRef
  • Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients
    Rui-Min Lai, Shan Lin, Miao-Miao Wang, Na Li, Jia-Hui Zhou, Xiao-Yu Lin, Tian-Bin Chen, Yue-Yong Zhu, Qi Zheng
    World Journal of Hepatology.2023; 15(8): 964.     CrossRef
  • Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV–HIV Co-infected Adults
    Richard K. Sterling, Wendy C. King, Mandana Khalili, David E. Kleiner, Amanda S. Hinerman, Mark Sulkowski, Raymond T. Chung, Mamta K. Jain, M auricio Lisker-Melman, David K. Wong, Marc G. Ghany
    Digestive Diseases and Sciences.2022; 67(2): 676.     CrossRef
  • Should We Treat Immune Tolerant Chronic Hepatitis B? Lessons from Asia
    Madhumita Premkumar, Yogesh K. Chawla
    Journal of Clinical and Experimental Hepatology.2022; 12(1): 144.     CrossRef
  • Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection
    Si Ho Kim, Eun Ju Cho, Boo‐ok Jang, Kyunghan Lee, Jae Kyun Choi, Gwang Hyeon Choi, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Yun Bin Lee, Jeong‐Hwan Yoon, Jin‐Wook Kim, Sook‐Hyang Jeong, Eun Sun Jang
    Liver International.2022; 42(2): 320.     CrossRef
  • Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver
    Mi Na Kim, Kyungdo Han, Juhwan Yoo, Seong Gyu Hwang, Sang Hoon Ahn
    Alimentary Pharmacology & Therapeutics.2022; 55(1): 97.     CrossRef
  • Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC
    Lei Liu, Si Xie, Yu-Xian Teng, Zhu-Jian Deng, Kang Chen, Hao-Tian Liu, Rong-Rui Huo, Xiu-Mei Liang, Ping-Ping Guo, Da-Long Yang, Liang Ma, Bang-De Xiang, Le-Qun Li, Jian-Hong Zhong
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Severe Hepatic Steatosis Is Associated With Low-Level Viremia and Advanced Fibrosis in Patients With Chronic Hepatitis B in North America
    Hin Hin Ko, Nishi H. Patel, Sarah Haylock-Jacobs, Karen Doucette, Mang M. Ma, Curtis Cooper, Erin Kelly, Magdy Elkhashab, Edward Tam, Robert Bailey, Alexander Wong, Gerald Minuk, Philip Wong, Scott K. Fung, Giada Sebastiani, Alnoor Ramji, Carla S. Coffin
    Gastro Hep Advances.2022; 1(1): 106.     CrossRef
  • MAFLD is Associated with the Risk of Liver Fibrosis and Inflammatory Activity in HBeAg-Negative CHB Patients
    Xiaoman Chen, Jing Zhou, Lili Wu, Xiang Zhu, Hong Deng
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 673.     CrossRef
  • Validation for models for tumor recurrence after liver transplantation in hepatectomy patients
    Sung Joon Kim, Jong Man Kim, Nam-Joon Yi, Gyu-Seong Choi, Kwang-Woong Lee, Kyung-Suk Suh, Jae-Won Joh
    Annals of Surgical Treatment and Research.2022; 102(3): 131.     CrossRef
  • A Novel Noninvasive Diagnostic Model of HBV-Related Inflammation in Chronic Hepatitis B Virus Infection Patients With Concurrent Nonalcoholic Fatty Liver Disease
    Xuemei Tao, Lin Chen, Youfei Zhao, Yonggang Liu, Ruifang Shi, Bei Jiang, Yuqiang Mi, Liang Xu
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Hepatitis B Core-Related Antigen Is Useful for Predicting Phase and Prognosis of Hepatitis B e Antigen-Positive Patients
    Han Ah Lee, Hyun Woong Lee, Younhee Park, Hyon-Suk Kim, Yeon Seok Seo
    Journal of Clinical Medicine.2022; 11(6): 1729.     CrossRef
  • MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
    Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura
    Clinical and Molecular Hepatology.2022; 28(2): 150.     CrossRef
  • Precision medicine in the era of potent antiviral therapy for chronic hepatitis B
    Eileen L. Yoon, Dae Won Jun
    Journal of Gastroenterology and Hepatology.2022; 37(7): 1191.     CrossRef
  • Metabolic Risk Factors Are Associated with the Disease Severity and Prognosis of Hepatitis B Virus-Related Acute on Chronic Liver Failure
    Lu Chen, Jinjin Dai, Qing Xie, Xiaolin Wang, Wei Cai
    Gut and Liver.2022; 16(3): 456.     CrossRef
  • Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia
    Ming Yang, Lai Wei
    Liver International.2022; 42(9): 1981.     CrossRef
  • Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
    Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim
    Clinical and Molecular Hepatology.2022; 28(3): 425.     CrossRef
  • Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease
    Han Ah Lee, Seung-seob Kim, Jin-Young Choi, Yeon Seok Seo, Beom Jin Park, Ki Choon Sim, Seung Up Kim
    Abdominal Radiology.2022; 47(11): 3733.     CrossRef
  • Clinical impact and mechanisms of hepatitis B virus infection concurrent with non-alcoholic fatty liver disease
    Xin Tong, Yu Song, Shengxia Yin, Jian Wang, Rui Huang, Chao Wu, Junping Shi, Jie Li
    Chinese Medical Journal.2022; 135(14): 1653.     CrossRef
  • Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name
    Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen
    Clinical and Molecular Hepatology.2022; 28(4): 790.     CrossRef
  • Progress in understanding of association between metabolic associated fatty liver disease and viral infectious diseases
    Zhao-Chun Chi
    World Chinese Journal of Digestology.2022; 30(18): 783.     CrossRef
  • Interaction and Possible Mechanism between Non-Alcoholic Fatty Liver Disease and Chronic Hepatitis B
    博诗 陈
    Advances in Clinical Medicine.2022; 12(11): 10453.     CrossRef
  • Radiomics Analysis of Magnetic Resonance Proton Density Fat Fraction for the Diagnosis of Hepatic Steatosis in Patients With Suspected Non-Alcoholic Fatty Liver Disease
    Ki Choon Sim, Min Ju Kim, Yongwon Cho, Hyun Jin Kim, Beom Jin Park, Deuk Jae Sung, Na Yeon Han, Yeo Eun Han, Tae Hyung Kim, Yoo Jin Lee
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Clinical study of ganshuang granule combined with tenofovir in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease
    Changtian Su, Qin Yang
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • NAFLD and HBV interplay - related mechanisms underlying liver disease progression
    Evanthia Tourkochristou, Stelios F. Assimakopoulos, Konstantinos Thomopoulos, Markos Marangos, Christos Triantos
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Metabolic syndromes, hepatitis B virus (HBV), and hepatitis C virus as three factors involved in the development of hepatic steatosis: a systematic review and meta-analysis
    Masoud Keikha, Amirhossein Sahebkar, Tannaz Jamialahmadi, Mohsen Karbalaei
    Reviews and Research in Medical Microbiology.2022; 33(3): 139.     CrossRef
  • Secondary prevention of hepatitis B virus‐related hepatocellular carcinoma with current antiviral therapies
    Jonggi Choi, Young‐Suk Lim
    The Kaohsiung Journal of Medical Sciences.2021; 37(4): 262.     CrossRef
  • HRD1 attenuates the high uptake of [18F]FDG in hepatocellular carcinoma PET imaging
    Ai-Mei Li, Xia-Wen Lin, Jing-Tao Shen, Min Li, Qi-Huang Zheng, Zheng-Yang Zhou, Ming Shi
    Nuclear Medicine and Biology.2021; 96-97: 27.     CrossRef
  • The FIB-4 Index Is a Useful Predictor for the Development of Hepatocellular Carcinoma in Patients with Coexisting Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B
    Minah Kim, Yeonju Lee, Jun Sik Yoon, Minjong Lee, So Shin Kye, Sun Woong Kim, Yuri Cho
    Cancers.2021; 13(10): 2301.     CrossRef
  • Association of Metabolic Risk Factors With Risks of Cancer and All‐Cause Mortality in Patients With Chronic Hepatitis B
    Yun Bin Lee, Hyemi Moon, Jeong‐Hoon Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Fabien Zoulim, Juneyoung Lee, Jung‐Hwan Yoon
    Hepatology.2021; 73(6): 2266.     CrossRef
  • Pyroptosis: mechanisms and diseases
    Pian Yu, Xu Zhang, Nian Liu, Ling Tang, Cong Peng, Xiang Chen
    Signal Transduction and Targeted Therapy.2021;[Epub]     CrossRef
  • Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B
    Laurens A. van Kleef, Hannah S.J. Choi, Willem P. Brouwer, Bettina E. Hansen, Keyur Patel, Robert A. de Man, Harry L.A. Janssen, Robert J. de Knegt, Milan J. Sonneveld
    JHEP Reports.2021; 3(5): 100350.     CrossRef
  • Systematic review with meta‐analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B
    Qi Zheng, Biyao Zou, Yuankai Wu, Yeehui Yeo, Huizhen Wu, Christopher D Stave, Ramsey C. Cheung, Mindie H. Nguyen
    Alimentary Pharmacology & Therapeutics.2021; 54(9): 1100.     CrossRef
  • Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy
    Rong Fan, Junqi Niu, Hong Ma, Qing Xie, Jun Cheng, Huiying Rao, Xiaoguang Dou, Jianping Xie, Wei Zhao, Jie Peng, Zhiliang Gao, Hongbo Gao, Xinyue Chen, Jinjun Chen, Qiang Li, Hong Tang, Zhengang Zhang, Hong Ren, Mingliang Cheng, Xieer Liang, Chaonan Zhu,
    Alimentary Pharmacology & Therapeutics.2021; 54(3): 329.     CrossRef
  • Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy
    Joo Hyun Oh, Hye Won Lee, Dong Hyun Sinn, Jun Yong Park, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Wonseok Kang, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Yong-Han Paik
    Hepatology International.2021; 15(4): 892.     CrossRef
  • Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion
    Yi-Wen Shi, Rui-Xu Yang, Jian-Gao Fan
    World Journal of Gastroenterology.2021; 27(26): 3971.     CrossRef
  • The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
    Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 467.     CrossRef
  • REPLY:
    Yun Bin Lee, Juneyoung Lee
    Hepatology.2021; 74(2): 1135.     CrossRef
  • Reply
    Hye Won Lee, Beom Kyung Kim
    Clinical Gastroenterology and Hepatology.2020; 18(1): 264.     CrossRef
  • Magnetic resonance imaging of obesity and metabolic disorders: Summary from the 2019 ISMRM Workshop
    Houchun H. Hu, Rosa Tamara Branca, Diego Hernando, Dimitrios C. Karampinos, Jürgen Machann, Charles A. McKenzie, Holden H. Wu, Takeshi Yokoo, S. Sendhil Velan
    Magnetic Resonance in Medicine.2020; 83(5): 1565.     CrossRef
  • Abnormal CD44 activation of hepatocytes with nonalcoholic fatty accumulation in rat hepatocarcinogenesis
    Miao Fang, Min Yao, Jie Yang, Wen-Jie Zheng, Li Wang, Deng-Fu Yao
    World Journal of Gastrointestinal Oncology.2020; 12(1): 66.     CrossRef
  • Chronic hepatitis B and non‐alcoholic fatty liver disease: Conspirators or competitors?
    Jianbin Zhang, Shuangzhe Lin, Daixi Jiang, Mengting Li, Yuanwen Chen, Jun Li, Jiangao Fan
    Liver International.2020; 40(3): 496.     CrossRef
  • Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B
    Jonggi Choi, Gi-Ae Kim, Seungbong Han, Young-Suk Lim
    American Journal of Gastroenterology.2020; 115(3): 406.     CrossRef
  • Approach to the patient with chronic hepatitis B and decompensated cirrhosis
    Mitchell L. Shiffman
    Liver International.2020; 40(S1): 22.     CrossRef
  • Presence of Hepatic Steatosis Does Not Increase the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Over Long Follow-Up
    Chong Teik Lim, George Boon Bee Goh, Huihua Li, Tony Kiat-Hon Lim, Wei Qiang Leow, Wei Keat Wan, Rafay Azhar, Wan Cheng Chow, Rajneesh Kumar
    Microbiology Insights.2020;[Epub]     CrossRef
  • Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B
    Han Ah Lee, Yeon Seok Seo, Seung Up Kim
    Gastroenterology.2020; 158(8): 2310.     CrossRef
  • Radiologic Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Suppressed Chronic Hepatitis B
    Hyeki Cho, Young Chang, Jeong-Hoon Lee, Young Youn Cho, Joon Yeul Nam, Yun Bin Lee, Dong Ho Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jeong Min Lee, Jung-Hwan Yoon
    Journal of Clinical Gastroenterology.2020; 54(7): 633.     CrossRef
  • A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B
    Hira Hanif, Muzammil M. Khan, Mukarram J. Ali, Pir A. Shah, Jinendra Satiya, Daryl T.Y. Lau, Aysha Aslam
    Microorganisms.2020; 8(10): 1526.     CrossRef
  • Letter: fatty liver disease could have been a confounding factor for phase change in patients with chronic hepatitis B in the immune‐tolerant phase—authors' reply
    Han Ah Lee, Seung Up Kim
    Alimentary Pharmacology & Therapeutics.2020; 52(6): 1094.     CrossRef
  • The Effects of Hepatic Steatosis on the Natural History of HBV Infection
    Idrees Suliman, Noha Abdelgelil, Farah Kassamali, Tarek I. Hassanein
    Clinics in Liver Disease.2019; 23(3): 433.     CrossRef
  • 13,853 View
  • 381 Download
  • 92 Web of Science
  • Crossref

Viral hepatitis

Association between apolipoprotein E genotype, chronic liver disease, and hepatitis B virus
Seun Joo Ahn, Dong Kyu Kim, Soon Sun Kim, Chang Bum Bae, Hyo Jung Cho, Han Gyeol Kim, Young Jip Kim, Joo Ho Lee, Hyo Jin Lee, Mi Yeon Lee, Kee Bum Kim, Jin Hee Cho, Sung Won Cho, Jae Youn Cheong
Korean J Hepatol 2012;18(3):295-301.
Published online September 25, 2012
DOI: https://doi.org/10.3350/cmh.2012.18.3.295
Background/Aims

Apolipoprotein E (ApoE) plays an important role in regulating lipid and lipoprotein metabolism, and ApoE genotypes are known to affect plasma lipoprotein concentrations. We investigated whether ApoE genotype determines the disease outcome in hepatitis B virus (HBV)-infected individuals, and verified the association between ApoE genotype and the occurrence of hepatocellular carcinoma (HCC) in patients with chronic liver diseases of various etiologies.

Methods

This hospital-based, case-controlled study enrolled 156 subjects (47 healthy controls, 50 HBV-related liver cirrhosis patients, and 59 HCC patients). ApoE genotypes were determined using PCR-based ApoE genotyping kits. The biological significance of ApoE genotype was verified by measuring serum ApoE levels using an ELISA kits.

Results

The ε3 allele was the most common allele, with allele frequencies among the entire cohort of 5.8%, 84.3%, and 9.9% for the ε2, ε3, and ε4 alleles, respectively. Significantly more of those patients carrying the ε3/3 genotype had developed liver cirrhosis compared to the control subjects. Being an ApoE4 carrier was associated with a lower probability of developing liver cirrhosis. The allele frequencies and genotype distribution of ApoE did not differ significantly between the liver cirrhosis and HCC patients. The serum level of ApoE was significantly higher in patients with liver cirrhosis than in the healthy controls, but did not differ significantly with the ApoE genotype.

Conclusions

The ApoE ε3/3 genotype frequency was higher in patients with HBV-associated liver cirrhosis than in the controls.

Citations

Citations to this article as recorded by  Crossref logo
  • A comprehensive understanding of HDL-associated apolipoproteins: future potential biomarker in sepsis
    Jingjing Ning, Tiantian Liu, Yilin Zhao, Chunxia Wang
    Expert Review of Molecular Diagnostics.2026; 26(1): 61.     CrossRef
  • Lipid‐Lowering Drugs and Pulmonary Vascular Disease: A Mendelian Randomization Study
    Xingya Yuan, Peiwei Hong, JinQiu Zhou
    Pulmonary Circulation.2025;[Epub]     CrossRef
  • HDL-based therapeutics: A promising frontier in combating viral and bacterial infections
    Alankrita Rani, Julia T. Stadler, Gunther Marsche
    Pharmacology & Therapeutics.2024; 260: 108684.     CrossRef
  • The Culprit Behind HBV-Infected Hepatocytes: NTCP
    Shenghao Li, Liyuan Hao, Jiali Deng, Junli Zhang, Fei Yu, Fanghang Ye, Na Li, Xiaoyu Hu
    Drug Design, Development and Therapy.2024; Volume 18: 4839.     CrossRef
  • Hepatitis B Virus Targets Lipid Transport Pathways to Infect Hepatocytes
    Knud Esser, Xiaoming Cheng, Jochen M. Wettengel, Julie Lucifora, Lea Hansen-Palmus, Katharina Austen, Armando A. Roca Suarez, Sarah Heintz, Barbara Testoni, Firat Nebioglu, Minh Tu Pham, Shangqing Yang, Alma Zernecke, Dirk Wohlleber, Marc Ringelhan, Mathi
    Cellular and Molecular Gastroenterology and Hepatology.2023; 16(2): 201.     CrossRef
  • Apolipoprotein E and viral infection: Risks and Mechanisms
    Feng Chen, Qiongwei Ke, Wenyan Wei, Lili Cui, Yan Wang
    Molecular Therapy - Nucleic Acids.2023; 33: 529.     CrossRef
  • Apolipoprotein E, a Crucial Cellular Protein in the Lifecycle of Hepatitis Viruses
    Yannick Tréguier, Anne Bull-Maurer, Philippe Roingeard
    International Journal of Molecular Sciences.2022; 23(7): 3676.     CrossRef
  • Risk Factors for Severe COVID-19 and Hepatitis C Infections: The Dual Role of Apolipoprotein E4
    Felipe B. Lima, Karine C. Bezerra, José Carlos R. Nascimento, Gdayllon C. Meneses, Reinaldo B. Oriá
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Apolipoprotein E polymorphism influences orthotopic liver transplantation outcomes in patients with hepatitis C virus-induced liver cirrhosis
    José Carlos Rodrigues Nascimento, Lianna C Pereira, Juliana Magalhães C Rêgo, Ronaldo P Dias, Paulo Goberlânio B Silva, Silvio Alencar C Sobrinho, Gustavo R Coelho, Ivelise Regina C Brasil, Edmilson F Oliveira-Filho, James S Owen, Pierluigi Toniutto, Rein
    World Journal of Gastroenterology.2021; 27(11): 1064.     CrossRef
  • Impact of apolipoprotein E genetic polymorphisms on liver disease: An essential review
    José C.R. Nascimento, Gabriella A. Matos, Lianna C. Pereira, Anderson E.C.C.B. Mourão, Aline M. Sampaio, Reinaldo B. Oriá, Pierluigi Toniutto
    Annals of Hepatology.2020; 19(1): 24.     CrossRef
  • APOE ϵ 4 modifies the relationship between infectious burden and poor cognition
    Chen Zhao, Kevin Strobino, Yeseon Park Moon, Ying Kuen Cheung, Ralph L. Sacco, Yaakov Stern, Mitchell S.V. Elkind
    Neurology Genetics.2020;[Epub]     CrossRef
  • ApoE deficiency promotes hepatic pathology by aggravating Th17/Treg imbalance in murine schistosomiasis japonica
    Fei Guan, Chongyang Zhang, Chunjie Jiang, Muziazia Lupemba Jacques, Yang Bai, Shengjun Lu, Wenqi Liu, Jiahui Lei
    Parasite Immunology.2020;[Epub]     CrossRef
  • Long-term effects of low-dose mouse liver irradiation involve ultrastructural and biochemical changes in hepatocytes that depend on lipid metabolism
    Malgorzata Lysek-Gladysinska, Anna Wieczorek, Anna Walaszczyk, Karol Jelonek, Artur Jozwik, Monika Pietrowska, Wolfgang Dörr, Dorota Gabrys, Piotr Widlak
    Radiation and Environmental Biophysics.2018; 57(2): 123.     CrossRef
  • Lipase inhibitor orlistat prevents hepatitis B virus infection by targeting an early step in the virus life cycle
    Knud Esser, Julie Lucifora, Jochen Wettengel, Katrin Singethan, Almut Glinzer, Alma Zernecke, Ulrike Protzer
    Antiviral Research.2018; 151: 4.     CrossRef
  • Causal relevance of circulating high-density lipoprotein cholesterol with cancer: a Mendelian randomization meta-analysis
    Chunhua Yang, Geng Tian, Jia Mi, Xiaodan Wei, Xuri Li, Xianglin Li, Wenming Wang, Bin Wang
    Scientific Reports.2015;[Epub]     CrossRef
  • Gene expression profiling of MYC-driven tumor signatures in porcine liver stem cells by transcriptome sequencing
    Rajagopal N Aravalli, Neil C Talbot, Clifford J Steer
    World Journal of Gastroenterology.2015; 21(7): 2011.     CrossRef
  • The role of von Willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: A quantitative proteomic based study
    Yi Liu, Xiwei Wang, Sanglin Li, Huaidong Hu, Dazhi Zhang, Peng Hu, Yixuan Yang, Hong Ren
    Journal of Proteomics.2014; 106: 99.     CrossRef
  • Association between apolipoprotein E genotype and cancer susceptibility: a meta-analysis
    R. Anand, S. S. Prakash, R. Veeramanikandan, Richard Kirubakaran
    Journal of Cancer Research and Clinical Oncology.2014; 140(7): 1075.     CrossRef
  • Human Plasma Lipid Modulation in Schistosomiasis Mansoni Depends on Apolipoprotein E Polymorphism
    Caíque Silveira Martins da Fonseca, Adenor Almeida Pimenta Filho, Bianka Santana dos Santos, César Augusto da Silva, Ana Lúcia Coutinho Domingues, James Stuart Owen, Vera Lúcia de Menezes Lima, Monica Uddin
    PLoS ONE.2014; 9(7): e101964.     CrossRef
  • Differential Regulation of Host Genes Including Hepatic Fatty Acid Synthase in HBV-Transgenic Mice
    Hongmin Zhang, Hong Li, Yixuan Yang, Sanglin Li, Hong Ren, Dazhi Zhang, Huaidong Hu
    Journal of Proteome Research.2013; 12(6): 2967.     CrossRef
  • 12,944 View
  • 81 Download
  • Crossref
Case Reports
Drug rash with eosinophilia and systemic symptoms syndrome following cholestatic hepatitis A: a case report
Jihyun An, Joo Ho Lee, Hyojeong Lee, Eunsil Yu, Dan Bi Lee, Ju Hyun Shim, Sunyoung Yoon, Yumi Lee, Soeun Park, Han Chu Lee
Korean J Hepatol 2012;18(1):84-88.
Published online March 22, 2012
DOI: https://doi.org/10.3350/kjhep.2012.18.1.84

Hepatitis A virus (HAV) infections occur predominantly in children, and are usually self-limiting. However, 75-95% of the infections in adults are symptomatic (mostly with jaundice), with the illness symptoms usually persisting for a few weeks. Atypical manifestations include relapsing hepatitis, prolonged cholestasis, and complications involving renal injury. Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome is a severe, drug-induced hypersensitivity reaction characterized by skin rash, fever, lymph-node enlargement, and internal organ involvement. We describe a 22-year-old male who presented with acute kidney injury and was diagnosed with prolonged cholestatic hepatitis A. The patient also developed DRESS syndrome due to antibiotic and/or antiviral treatment. To our knowledge, this is the first report of histopathologically confirmed DRESS syndrome due to antibiotic and/or antiviral treatment following HAV infection with cholestatic features and renal injury.

Citations

Citations to this article as recorded by  Crossref logo
  • Prolonged Cholestatic Hepatitis A With Transient Epstein-Barr Virus IgM Reactivity and Marked Hyperferritinemia in an HFE H63D Heterozygote
    Sara R Silva, Filipe Dias, Cláudia Ribeiro, Fátima Augusto, Cátia Albino
    Cureus.2026;[Epub]     CrossRef
  • Treatment of Prolonged Cholestasis with Systemic Steroid in Acute Hepatitis A: A Case Report
    Jae Hyun Yoon, Youngeun Seo, Sung Bum Cho
    Convergence Hepatology.2025; 1(1): 85.     CrossRef
  • Recent advances in hepatitis A virus research and clinical practice guidelines for hepatitis A virus infection in Japan
    Tatsuo Kanda, Reina Sasaki‐Tanaka, Koji Ishii, Ryosuke Suzuki, Jun Inoue, Atsunori Tsuchiya, Shingo Nakamoto, Ryuzo Abe, Keiichi Fujiwara, Osamu Yokosuka, Tian‐Cheng Li, Satoshi Kunita, Hiroshi Yotsuyanagi, Hiroaki Okamoto
    Hepatology Research.2024; 54(1): 4.     CrossRef
  • DRESS syndrome with cholecystitis in a child: A case report and literature review
    Ferdaous Chahed, Najah Ben Fadhel, Haifa Ben Romdhane, Zohra Chadli, Habib Besbes, Naceur Boughattas, Nadia Ben Fredj, Karim Aouam
    Therapies.2022; 77(5): 622.     CrossRef
  • Characterizing DRESS syndrome recurrence: a systematic review
    Ajay N. Sharma, Samantha Shwe, Vignesh Ravi, Melanie Miller, Natasha A. Mesinkovska, Nathan W. Rojek, Scott Worswick
    Archives of Dermatological Research.2021; 314(8): 721.     CrossRef
  • Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances
    Teresa Bellón
    Drug Safety.2019; 42(8): 973.     CrossRef
  • Variation of clinical manifestations according to culprit drugs in DRESS syndrome
    Da Woon Sim, Ji Eun Yu, Jiung Jeong, Jae‐Woo Jung, Hye‐Ryun Kang, Dong Yoon Kang, Young Min Ye, Young‐Koo Jee, Sujeong Kim, Jung‐Won Park, Min Gyu Kang, Sae Hoon Kim, Hye‐Kyung Park, Min‐Suk Yang, Gyu‐Young Hur, Jun Kyu Lee, Jeong‐Hee Choi, Yong Eun Kwon,
    Pharmacoepidemiology and Drug Safety.2019; 28(6): 840.     CrossRef
  • Allopurinol-induced DRESS syndrome mimicking biliary obstruction
    Hyung Gyu Choi, Junsu Byun, Chae Ho Moon, Jong Ho Yoon, Ki Young Yang, Su Cheol Park, Chul Ju Han
    Clinical and Molecular Hepatology.2014; 20(1): 71.     CrossRef
  • Dress Syndrome Induced by Sulphasalazine
    K. Pałgan, Z. Bartuzi
    European Journal of Inflammation.2014; 12(1): 187.     CrossRef
  • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
    S. Ständer, D. Metze, T. Luger, T. Schwarz
    Der Hautarzt.2013; 64(8): 611.     CrossRef
  • 10,693 View
  • 63 Download
  • Crossref
Osler-Weber-Rendu disease presenting with hepatocellular carcinoma: radiologic and genetic findings
Joo Ho Lee, Yung Sang Lee, Pyo Nyun Kim, Beom Hee Lee, Gu-Whan Kim, Han-Wook Yoo, Nae-Yun Heo, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Dong Jin Suh
Korean J Hepatol 2011;17(4):313-318.
Published online December 26, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.4.313

This is a case report of a 68-year-old man with hepatocellular carcinoma (HCC) accompanied by hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu disease, and hepatic vascular malformation. HHT is an autosomal dominant disorder of the fibrovascular tissue that is characterized by recurrent epistaxis, mucocutaneous telangiectasias, and visceral arteriovenous malformations. HHT is caused by mutation of the genes involved in the signaling pathway of transforming growth factor-β, which plays an important role in the formation of vascular endothelia. Hepatic involvement has been reported as occurring in 30-73% of patients with HHT. However, symptomatic liver involvement is quite rare, and the representative clinical presentations of HHT in hepatic involvement are high-output heart failure, portal hypertension, nodular regenerative hyperplasia, and symptoms of biliary ischemia. Some cases of HCC in association with HHT have been reported, but are very rare. We present herein the characteristic radiologic and genetic findings of HHT that was diagnosed during the evaluation and treatment of HCC.

Citations

Citations to this article as recorded by  Crossref logo
  • Abdominal imaging findings of hereditary hemorrhagic telangiectasia: a case series of seven patients and literature review
    Jiawei Liu, Jian Ling, Fen Yu, Lujie Li, Yuxin Wu, Qiaochu Zhao, Chenyu Song, Zhi Dong, Jifei Wang, Mimi Tang, Meicheng Chen, Siya Shi, Yanji Luo, Danyang Xu
    Chinese Journal of Academic Radiology.2025; 8(4): 268.     CrossRef
  • Hepatic manifestations of hereditary haemorrhagic telangiectasia
    Claire Kelly, Elisabetta Buscarini, Guido Manfredi, Stephen Gregory, Michael A. Heneghan
    Liver International.2024; 44(9): 2220.     CrossRef
  • Partial hepatectomy for a patient with Rendu–Osler–Weber disease: a case report
    Naoko Sekiguchi, Daisaku Yamada, Shogo Kobayashi, Kazuki Sasaki, Yoshifumi Iwagami, Yoshito Tomimaru, Takehiro Noda, Hidenori Takahashi, Yuichiro Doki, Hidetoshi Eguchi
    Surgical Case Reports.2023;[Epub]     CrossRef
  • Epidemiology, pathogenesis, diagnosis, surveillance, and management of hepatocellular carcinoma associated with vascular liver disease
    Debi Prasad, Mindie H. Nguyen
    The Kaohsiung Journal of Medical Sciences.2021; 37(5): 355.     CrossRef
  • Benign and malignant hepatocellular lesions in patients with vascular liver diseases
    Valérie Vilgrain, Valérie Paradis, Morgane Van Wettere, Dominique Valla, Maxime Ronot, Pierre-Emmanuel Rautou
    Abdominal Radiology.2018; 43(8): 1968.     CrossRef
  • A successful treatment for hepatocellular carcinoma with Osler–Rendu–Weber disease using radiofrequency ablation under laparoscopy
    Yoshinari Takaoka, Naoki Morimoto, Kouichi Miura, Hiroaki Nomoto, Kozue Murayama, Takuya Hirosawa, Shunji Watanabe, Takeshi Fujieda, Mamiko Ttsukui, Hirotoshi Kawata, Toshiro Niki, Norio Isoda, Makoto Iijima, Hironori Yamamoto
    Clinical Journal of Gastroenterology.2018; 11(6): 501.     CrossRef
  • Osler-Weber-Rendu Disease Presenting as Recurrent Portosystemic Encephalopathy in a 75-year-old Female Patient
    Junghoon Ha, Byoung Kwan Son, Sang Bong Ahn, Young Kwan Jo, Seong Hwan Kim, Yun Ju Jo, Young Sook Park, Yoon Young Jung
    The Korean Journal of Gastroenterology.2015; 65(1): 57.     CrossRef
  • Benign and malignant hepatocellular lesions in patients with vascular liver disease
    Valérie Vilgrain, Pierre-Emmanuel Rautou, Valérie Paradis, Maxime Ronot
    Clinical Liver Disease.2014; 3(6): 122.     CrossRef
  • 12,369 View
  • 65 Download
  • Crossref